This observational study will evaluate the course of treatment, the efficacy on anemia and the safety of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic kidney disease on dialysis. Eligible patients will be on either haemodialysis or peritoneal dialysis and treatment-naïve for or having had prior therapy with erythropoiesis stimulating agents (ESA). Data will be collected from each patient for 12 months.
Study Type
OBSERVATIONAL
Enrollment
419
Unnamed facility
Neuilly-sur-Seine, France
Haemoglobin levels
Time frame: Month 6
Mircera therapy (dosage, schedule, mode of application) in the treatment of anemia in clinical practice
Time frame: Month 6
Change in haemoglobin/haematocrit
Time frame: from baseline to Month 12
Biological parameters of anemia: transferrin saturation, serum ferritin, folates
Time frame: 12 months
Efficacy of dialysis (Kt/V, urea levels)
Time frame: 12 months
Safety: Incidence of adverse events
Time frame: 12 months
Compliance (treatment modification or discontinuation)
Time frame: 12 months
Quality of life: Short Form (SF-36) questionnaire
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.